Skip to content

Study · Animal study (in vivo) · mouse and rat · 2006

12 results

Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.

Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA

International journal of obesity (2005)14 Mar 2006Cited by 116 (Europe PMC)

PMID16534527 (opens in a new tab)DOI10.1038/sj.ijo.0803284 (opens in a new tab)PepBankPUB-16534527
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat-fed mice and rats, exenatide dose-dependently decreased food intake.

    In plain wordsIn mice and rats fed high-fat diets, exenatide reduced food intake in a dose-dependent manner.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFood intake
    Study

    Mice and ratsn: not reported in source

    High-fat-fed C57BL/6 mice and Sprague-Dawley rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3, 10 and 30 microg/kg/day · subcutaneous osmotic pumps · 4 weeksAs given in this study (Mice and rats).

    Source sentences

    Summary
    Exenatide treatment in mice and rats dose-dependently decreased food intake and body weight; significant reductions in body weight gain were observed throughout treatment at 10 and 30 microg/kg/day (P<0.05).
    1 context sentence
    Summary · context
    High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 microg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat-fed mice and rats, exenatide dose-dependently decreased body weight.

    In plain wordsIn mice and rats fed high-fat diets, exenatide reduced body weight in a dose-dependent manner.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    Mice and ratsn: not reported in source

    High-fat-fed C57BL/6 mice and Sprague-Dawley rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3, 10 and 30 microg/kg/day · subcutaneous osmotic pumps · 4 weeksAs given in this study (Mice and rats).

    Source sentences

    Summary
    Exenatide treatment in mice and rats dose-dependently decreased food intake and body weight; significant reductions in body weight gain were observed throughout treatment at 10 and 30 microg/kg/day (P<0.05).
    1 context sentence
    Summary · context
    High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 microg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat-fed mice and rats, exenatide reduced body weight gain throughout treatment.

    In plain wordsIn mice and rats, exenatide reduced weight gain throughout treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight gain
    Study

    Mice and ratsn: not reported in source

    High-fat-fed C57BL/6 mice and Sprague-Dawley rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 microg/kg/day · subcutaneous osmotic pumps · 4 weeksAs given in this study (Mice and rats).

    Source sentences

    Summary
    Exenatide treatment in mice and rats dose-dependently decreased food intake and body weight; significant reductions in body weight gain were observed throughout treatment at 10 and 30 microg/kg/day (P<0.05).
    1 context sentence
    Summary · context
    High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 microg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat-fed mice and rats, exenatide reduced body weight gain throughout treatment.

    In plain wordsIn mice and rats, exenatide reduced weight gain throughout treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight gain
    Study

    Mice and ratsn: not reported in source

    High-fat-fed C57BL/6 mice and Sprague-Dawley rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    30 microg/kg/day · subcutaneous osmotic pumps · 4 weeksAs given in this study (Mice and rats).

    Source sentences

    Summary
    Exenatide treatment in mice and rats dose-dependently decreased food intake and body weight; significant reductions in body weight gain were observed throughout treatment at 10 and 30 microg/kg/day (P<0.05).
    1 context sentence
    Summary · context
    High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 microg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat-fed mice and rats, reduced weight gain with exenatide accompanied a significant decrease in fat mass.

    In plain wordsIn mice and rats, exenatide-related lower weight gain accompanied lower fat mass.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFat mass
    Study

    Mice and ratsn: not reported in source

    High-fat-fed C57BL/6 mice and Sprague-Dawley rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3, 10 and 30 microg/kg/day · subcutaneous osmotic pumps · 4 weeksAs given in this study (Mice and rats).

    Source sentences

    Summary
    Decreased body weight gain was associated with a significant decrease in fat mass (P<0.05) with sparing of lean tissue.
    1 context sentence
    Summary · context
    High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 microg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat-fed mice and rats, exenatide-associated fat loss spared lean tissue.

    In plain wordsIn mice and rats, lean tissue was spared during exenatide-associated fat loss.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeLean tissue sparing
    Study

    Mice and ratsn: not reported in source

    High-fat-fed C57BL/6 mice and Sprague-Dawley rats
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3, 10 and 30 microg/kg/day · subcutaneous osmotic pumps · 4 weeksAs given in this study (Mice and rats).

    Source sentences

    Summary
    Decreased body weight gain was associated with a significant decrease in fat mass (P<0.05) with sparing of lean tissue.
    1 context sentence
    Summary · context
    High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 microg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat-fed mice and rats, exenatide significantly reduced plasma cholesterol.

    In plain wordsIn mice and rats, exenatide lowered blood cholesterol.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePlasma cholesterol
    Study

    Mice and ratsn: not reported in source

    High-fat-fed C57BL/6 mice and Sprague-Dawley rats
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    3, 10 and 30 microg/kg/day · subcutaneous osmotic pumps · 4 weeksAs given in this study (Mice and rats).

    Source sentences

    Summary
    Plasma cholesterol, triglycerides and insulin were also significantly reduced (P<0.05).
    1 context sentence
    Summary · context
    High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 microg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat-fed mice and rats, exenatide significantly reduced plasma triglycerides.

    In plain wordsIn mice and rats, exenatide lowered blood triglycerides.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePlasma triglycerides
    Study

    Mice and ratsn: not reported in source

    High-fat-fed C57BL/6 mice and Sprague-Dawley rats
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    3, 10 and 30 microg/kg/day · subcutaneous osmotic pumps · 4 weeksAs given in this study (Mice and rats).

    Source sentences

    Summary
    Plasma cholesterol, triglycerides and insulin were also significantly reduced (P<0.05).
    1 context sentence
    Summary · context
    High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 microg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In high-fat-fed mice and rats, exenatide significantly reduced plasma insulin.

    In plain wordsIn mice and rats, exenatide lowered blood insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePlasma insulin
    Study

    Mice and ratsn: not reported in source

    High-fat-fed C57BL/6 mice and Sprague-Dawley rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3, 10 and 30 microg/kg/day · subcutaneous osmotic pumps · 4 weeksAs given in this study (Mice and rats).

    Source sentences

    Summary
    Plasma cholesterol, triglycerides and insulin were also significantly reduced (P<0.05).
    1 context sentence
    Summary · context
    High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 microg/kg/day) for 4 weeks via subcutaneously implanted osmotic pumps.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In fasted rats, a single exenatide injection significantly reduced food intake.

    In plain wordsIn rats, a single exenatide injection reduced food intake.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAcute food intake
    Study

    Ratn: not reported in source

    Fasted Sprague-Dawley rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    10 microg/kg · intraperitoneal · Single injectionAs given in this study (Rat).

    Source sentences

    Summary
    Exenatide at 10 microg/kg significantly reduced food intake (P<0.05) but failed to induce kaolin intake.
    1 context sentence
    Summary · context
    Kaolin consumption and locomotor activity were measured in fasted Sprague-Dawley rats following a single intraperitoneal injection of exenatide (0.1-10 microg/kg).
  11. 11AnimalAnimal study (in vivo)Safety outcome

    In fasted rats, exenatide did not induce kaolin intake.

    In plain wordsIn rats, exenatide did not induce kaolin intake.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeKaolin intake
    Study

    Ratn: not reported in source

    Fasted Sprague-Dawley rats
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    10 microg/kg · intraperitoneal · Single injectionAs given in this study (Rat).

    Source sentences

    Summary
    Exenatide at 10 microg/kg significantly reduced food intake (P<0.05) but failed to induce kaolin intake.
    1 context sentence
    Summary · context
    Kaolin consumption and locomotor activity were measured in fasted Sprague-Dawley rats following a single intraperitoneal injection of exenatide (0.1-10 microg/kg).
  12. 12AnimalAnimal study (in vivo)Safety outcome

    In rats, exenatide generally reduced locomotor activity at doses that reduced food intake, with slightly higher doses needed for significance.

    In plain wordsIn rats, exenatide generally reduced movement at appetite-reducing doses, with slightly higher doses needed for significant changes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLocomotor activity
    Study

    Ratn: not reported in source

    Fasted Sprague-Dawley rats
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    0.1-10 microg/kg · intraperitoneal · Single injectionAs given in this study (Rat).

    Source sentences

    Summary
    In general, locomotor activity was reduced at doses of exenatide that decreased food intake, although a slightly higher dose was required to produce significant changes in activity.
    1 context sentence
    Summary · context
    Kaolin consumption and locomotor activity were measured in fasted Sprague-Dawley rats following a single intraperitoneal injection of exenatide (0.1-10 microg/kg).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.